Population pharmacodynamic and pharmacokinetic modeling via mixed effects

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 3, 2000, Pages 314-330

  Piotrovsky, Vladimir K ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Mixed effects modeling; Pharmacodynamics; Pharmacokinetics; Populations

Indexed keywords

ANALYTIC METHOD; ARTICLE; DATA ANALYSIS; OUTCOMES RESEARCH; POPULATION RESEARCH; SIMULATION; STATISTICAL ANALYSIS;

EID: 0033920512     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Aarons L: Population pharmacokinetics. Int J Clin Pharmacol Ther Toxicol (1992) 30:520-522.
2. Aarons L, Balant LP, Mentre F, Rowland M, Steimer JL, Vozeh S: Practical experience and issues in designing and performing population pharmacokinetic/ pharmacodynamic studies. Eur J Clin Pharmacol (1996) 49:251-254. • Consensus document of an expert meeting to discuss issues relating to the design of population studies that was held in Brussels in March 1995, under the auspices of European Co-operation in Science and Technology (COST), Medicine (B1) Programme.
3. Baud FJ: Pharmacokinetic-pharmacodynamic relationships. How are they useful in human toxicology? Toxicol Lett (1998) 103:643-648.
4. Ebling WF, Levy G: Population pharmacodynamics: Strategies for concentration-and effect-controlled clinical trials. Ann Pharmacother (1996) 30:12-19. • An important work that evaluates various strategies for drug concentration- and effect-controlled clinical trials in the context of studies of population pharmacodynamics.
5. Jeriing M: Population pharmacokinetics and pharmacodynamics: Potential use for gathering doseconcentration-response. Eur J Drug Metab Pharmacokinet (1996)21:113-121.
6. Lemmens H: Pharmacokinetic and pharmacodynamic modeling in drug development. In: Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. D'Argenio DZ (Ed), Plenum Press, New York, USA (1995):61-68.
7. Lieberman R, McMichael J: Role of pharmacokineticpharmacodynamic principles In rational and cost-effective drug development Ther Drug Monit (1996) 18:423-428.
8. Meibohm B, Derendorf H: Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Int J Clin Pharmacol 77ie/-(1997) 35:401-413. • It is concluded that the expanded use of PK-PD modeling is highly beneficial for drug development, as well as applied pharmacotherapy, and will most likely improve the current state of applied therapeutics.
9. Minto C, Schnider T: Expanding clinical applications of population pharmacodynamic modeling. Br J Clin Pharmacol (1998) 46:321-333. • One of the latest reviews on population PK-PD modeling.
10. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, Van Brummelen P: An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann-La Roche. Clin Pharmacokinet (1997) 33:142-52.
11. Samara E, Granneman R: Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet (1997) 32:294-312.
12. Sheiner LB, Ludden TM: Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol (1992)32:185-209.
13. Steimer JL, Vozeh S, Racine-Poon A, Holford N, O'Neill R: The population approach: Rationale, methods and applications in clinical pharmacology and drug development. In: Pharmacokinetics of Drugs. Welling PG, Balant LP (Eds), Springer-Verlag, Berlin, Germany (1994):405-450. •• A comprehensive overview of mixed-effects modeling in general and population PK-PD modeling in particular. One of the most complete lists of relevant literature.
14. Sun H, Fadiran EO, Jones CD, Lesko L, Huang SM, Higgins K, Hu C, Machado S, Maldonado S, Williams R, Hossain M, Ette El: Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet (1999) 37:41-58.
15. Tett SE, Holford NH, McLachlan AJ: Population pharmacokinetics and pharmacodynamics: An underutilized resource. Drug InfJ (1998) 32:693-710.
16. Wright PM: Population-based pharmacokinetic analysis: Why do we need it, what is it, and what has it told us about anaesthetics? BrJAnaesth (1998) 80:488-501.
17. Yuh L, Beal S, Davidian M, Harrison F, Hester A, Kowalski K, Vonesh E, Wolfinger R: Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography. Biometrics (1994) 50:566-575.
18. Welling PG (Ed): Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition, American Chemical Society, Washington DC, USA (1997).
19. Hale M, Gillespie WR, Gupta SK, Tuk B, Holford NH: Clinical trial simululation. Streamlining your drug development process. Appl Clin Trials (1996) 8:35-40. •• One of the first publications on trial simulations and computerassisted trial design.
20. Vonesh EF, Chinchilli VM (Eds): Linear and Non-linear Models for the Analysis of Repeated Measurements. Marcel Dekker Inc. New York, USA (1997). • A detailed monograph on mixed-effects modeling that covers various mathematical approaches.
21. Aarons L: Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet (1999) 36:255-264.
22. Bennett JE, Wakefield JC: A comparison of a Bayesian population method with two methods as implemented in commercially available software. J Pharmacokinet Biopharm (1996)24:403-432.
23. Best NG, Tan KK, Gilks WR, Spiegelhalter DJ: Estimation of population pharmacokinetics using the Gibbs sampler. J Pharmacokinet Biopharm (1995) 23:407-435.
24. Davidian M, Giltinan DM (Eds): Non-linear Models for Repeated Measurement Data. Chapman & Hall, London, UK (1995). •• The most frequently cited monograph on mixed-effects modeling.
25. Galecki AT: NLMEM: A new SAS/1ML macro for hierarchical non-linear models. Comput Methods Programs Biomed (1998)55:207-216.
26. Mentre F, Gomeni R: A two-step iterative algorithm for estimation in non-linear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat (1995)5:141-158.
27. Roe DJ: Comparison of population pharmacokinetic modeling methods using simulated data: Results from the Population Modeling Workgroup. Stat Med (1997) 16:1241-1257. • Comparison of various softwares for mixed-effects modeling.
28. Smith A, Wakefield J: The hierarchical Bayesian approach to population pharmacokinetic modeling. Int J Biomed Comput (1994) 36:35-42.
29. Wakefield JL, Smith AF, Racine A, Gelfand AE: Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. ApplStat (1994) 43:201-221.
30. Wakefield J, Racine-Poon A: An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Stat Med (1995) 14:971-986.
31. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG: Population pharmacokineticpharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther (1998) 64:622-635.
32. Karlsson MO, Port RE, Ratain MJ, Sheiner LB: A population model for the leukopenic effect of etoposide. Clin Pharmacol T7ier(1995) 57:325-334.
33. Verotta D: Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Crit Rev Biomed Eng (1996) 24:73-139.
34. Park K, Verotta D, Blaschke TF, Sheiner LB: A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm (1997) 25:615-642.
35. Fattinger KE, Verotta D: A non-parametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples. J Pharmacokinet Biopharm (1995) 23:581-610.
36. Fattinger KE, Verotta D: A non-parametric subject-specific population method for deconvolution: II. External validation. J Pharmacokinet Biopharm (1995) 23:611-634.
37. Karlsson MO, Sheiner LB: The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm (1993) 21:735-750. •• The first publication to introduce the concept of interoccasion variability in population PK-PD modeling.
38. Lalonde RL, Quellet D, Kimanani EK, Potvin D, Vaughan LM, Hill MR: Comparison of different methods to evaluate population dose-response and relative potency: Importance of inter-occasion variability. J Pharmacokinet Biopharm (1999) 27:67-83.
39. Holford NH: Population models for Alzheimer's and Parkinson's diseases. In: COST B1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aarons L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):97-104. • An interesting example of using population modeling. An attempt is made to construct disease, placebo and drug response models.
40. Bellissant E, Sebille V, Paintaud G: Methodological issues in pharmacokinetic-pharmacodynamic modeling. Clin Pharmacokinet (1998) 35:151-166.
41. Bouillon T, Meineke l, Port R, Hildebrandt R, Günther K, Gundert-Remy U: Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Eur J Clin Pharmacol (1996) 51:153-160.
42. Bouillon T, Schmidt C, Garstka G, Heimbach D, Staffers! D, Schwilden H, Hoeft A: Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil. Anesthesiology (1999) 91:144-155.
43. Bressolle F, Audran M, Gareau R, Baynes RD, Guidicelli C, Gomeni R: Population pharmacodynamics for monitoring epoetin in athletes. Clin Drug Invest (1997) 14:233-242.
44. Bressolle F, Gomeni R: Predictive performance of a semiparametric method to estimate population pharmacokinetic parameters using NONMEM. J Pharmacokinet Biopharm (1998) 26:349-361.
45. Brynne L, Kartsson MO, Paalzow LK: Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia. J Pharmacol Exp Ther (1998) 286:1152-1158.
46. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL: Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development Anesthesiology (1997) 86:10-23.
47. Minto CF, Schnider TW, Shafer SL: Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology (1997) 86:24-33.
48. Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, Masuhara K, Tanaka Y, Takahashi H, Nagai H, Kalo K, Koshiba Y, Igarashi T, Yokoyama A, Kinameri K, Kato T, Kurita Y: Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program. J Clin Pharmacol (1998) 38:1025-1034.
49. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, FunckBrentano C, Jaillon P: Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol TAier(1998) 64:192-203.
50. Rehberg B, Bouillon T, Zinserling J, Hoeft A: Comparative pharmacodynamic modeling of the electroencephalographyslowing effect of isoflurane, sevoflurane, and desflurane. Anesthesiology (1999) 91:397-405.
51. Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A: Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. Clin Pharmacol Ther (1997) 62:426-435.
52. Schmith VD, Fiedler-Kelly J, Phillips L, Graseia TH: Prospective use of population pharmacokinetics/ pharmacodynamics in the development of cisatracurium. Pharm Res (1997) 14:91-97.
53. Schnider TW, Minto CF, Bruckert H, Mandema JW: Population pharmacodynamic modeling and covariate detection for central neural blockade. Anesthesiology (1996) 85:502-512.
54. Snoeck E, Piotrovsky V, Jacqmin P, Lins RL, Van Peer A, Danhof M, Woestenborghs Ft, Van Gool R, Dupont AG, Heykants J: Population analysis of the non-linear red blood cell partitioning of draflazine following various Infusion durations. Eur J Clin Pharmacol (1997) 53:57-63.
55. Snoeck E, Piotrovsky V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont AG, Heykants J: Population analysis of the nonlinear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. Br J Clin Pharmacol (1997) 43:603-612.
56. Wade JR, Sambol NO: Felodipine population doseresponse and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther (1995)57:569-581.
57. Rosenbaum SE, Carter AA, Dudley MM: Population pharmacokinetics: Fundamentals,. methods and applications. Drug Dev Ind Pharm (1995) 21:1115-1141.
58. Vozeh S: The population approach 1991-1997. In: COST B1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aarons L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):3-8.
59. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO: The pharmacokinetic modeling of Gl 19874 5 (dutasteride), a compound with parallel linear and nonlinear elimination. BrJ Clin Pharmacol (1999) 47:53-58.
60. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R: Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 27:1220-1223.
61. Bressolie F, Audran M, Gareau R, Pham TN, Gomeni R: Comparison of a direct and indirect population pharmacodynamic model: Application to recombinant human erythropoietin in athletes. J Pharmacokinet Biopharm (1997) 25:263-275.
62. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL: Remifentanil versus alfentanil: Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology (1996) 84:821-833.
63. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R: A general model for time-dissociated pharmacokineticpharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther(î998) 63:11-25. • A general model for delayed effects which gives an improved description of the concentration-response relationship and more accurate predictions of the ultimate effect when doses and schedules are varied.
64. Marino MT, Schuster BG, Brueckner RP, Lin E, Kaminskis A, Lasseter KC: Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J Clin Pharmacol (1998) 38:227-235.
65. Wakelkamp M, Alvan G, Scheinin H, Gabrielsson J: The influence of drug input rate on the development of tolerance to frusemide. BrJ Clin Pharmacol (1998) 46:479-487.
66. Dayneka NL, Garg V, Jusko WJ: Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 21:457-478. •• The first publication summarizing various versions of an indirect response model.
67. Brynne L, Paalzow LK, Karlsson MO: Mechanism-based modeling of rebound tachycardia after chronic Ipropranolol infusion in spontaneous hypertensive rats. J PharmacolExp T/7er(1999) 290:664-671.
68. Chakraborty A, Krzyzanski W, Jusko WJ: Mathematical modeling of circadian cortisol concentrations using indirect response models: Comparison of several methods. J Pharmacokinet Biopharm (1999) 27:23-43.
69. Perron GM, Pyszczynski NA, Jusko WJ: Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm (1999) 27:1-21.
70. Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ: Time-dependent pharmacodynamic models in cancer chemotherapy: Population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a phase I trial of melphalan and BSO. Cancer Res (1995) 55:4507-4511.
71. Gisleskog PO, Hermann D, Hammartund-Udenaes M, Karlsson MO: Validation of a population pharmacokinetic/pharmacodynamic model for 5areductase inhibitors. EurJPharm Sei (1999) 8:291-299.
72. Gobburu JV, Agerso H, Jusko WJ. Ynddal L: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res (1999) 16:1412-1416.
73. Hayashi N, Kinoshita H, Yukawa E, Higuchi S: Pharmacokinetic analysis of subcutaneous erythropoietin administration with non-linear mixed effect model including endogenous production. Br J Clin Phanmacol (1998)46:11-19.
74. Karlsson MO, Wade JR, Loumaye E, Munafo A: A population model for the follicular growth in women treated with follicle stimulating hormone. Clin Pharmacol Ther (1997) 62:665-674.
75. Krzyzanski W, Jusko WJ: Characterization of pharmacodynamic recession slopes for direct and indirect response models. J Pharmacokinet Biopharm (1998) 26:409436.
76. Krzyzanski W, Jusko WJ: Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. J Pharmacokinet Biopharm (1998) 26:385-408.
77. Krzyzanski W, Jusko WJ: Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1997)25:107-123.
78. Lalonde RL, Gaudreault J, Karhu DA, Marriott TB: Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther( 999) 65:40-49.
79. Mathot RA, Geus WP: Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. Clin Pharmacol Ther (1999) 66:140-151.
80. Mentre F, Roussel F, Comets E, Plaud B, Diquet B, Montalescot G, Ankri A, Mallet A, Léchât P: Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol 7?7er(1998) 63:64-78.
81. Sharnia A, Ebling WF, Jusko WJ: Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sei (1998) 87:1577-1584. • The proposed model considers inhibition or stimulation of production of the response variable dependent on the amount of precursor which may accumulate or deplete after administration of some drugs.
82. Sharma A, Jusko WJ: Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J din P/7armaco/(1998) 45:229-239.
83. Sun YN, Jusko WJ: Role of baseline parameters in determining indirect pharmacodynamic responses. JPharm Sei (1999) 88:987-990.
84. Bagli M, Suverkrup R, Quadflieg R, Hoflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML: Pharmacokineticpharmacodynamic modeling of tolerance to the prolactinsecreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther (1999) 291:547554.
85. Fattinger K, Verotta D, Benowitz NL: Pharmacodynamics of acute tolerance to multiple nlcotinic effects in humans. J Pharmacol Exp T/7e/-(1997) 281:1238-1246.
86. Gardmark M, Brynne L, Hammartund-Udenaes M, Karlsson MO: Interchangeability and prédictive performance of empirical tolerance models. Clin Pharmacokinet (1999) 36:145-167. • A direct comparison of seven tolerance model performed for the first time.
87. Gieschke R, Reigner BG, Steimer JL: Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modeling. Int J Clin Pharmacol The;-(1997) 35:469-474.
88. Paalzow LK, Sjalander-Brynne L: Pharmacodynamic aspects of drug administration - tolerance development Adv Drug Deliv Rev (1998) 33:235-240.
89. Bailey JM, Gregg KM: A technique for population pharmacodynamic analysis of concentration-binary response data. Anesthesiology (1997) 86:825-835.
90. Bruno R, Hille D, Riva A, Vivier N, Huinnink WW, Van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burns HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/ Pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Onco/(1998) 16:187-196.
91. Drover DR, Lemmens HJ: Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. Anesthesiology (1998) 89:869-877.
92. Gupta SK, Sathyan G, Lindemulder EA, Ho PL, Sheiner LB, Aarons L: Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol T/ier(1999) 65:672-684.
93. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verppoten GA: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther(1998) 64:672-683.
94. Mandema JW, Stanski DR: Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther (1996) 60:619-635.
95. Shafer SL, Hu C: Managing pharmacodynamic variability in anesthesia: integrating the EEC, effect site, anesthetic concentrations and measures of anesthetic depth. In: COST B1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aarons L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):83-94.
96. Sheiner LB: A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol 77ier(1994) 56:309-322.
97. Somma J, Donner A, Zomorodi K, Sladen R, Ramsay J, Geller E, Shafer SL: Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery. Anesthesiology (1998) 89:1430-1443.
98. Xie M, Simpson DG: Regression modeling of ordinal data with nonzero baselines. Biometrics (1999) 55:308-316.
99. Christiansen CL, Morris CN: Hierarchical Poisson regression modeling. JAm StatAss (1997) 92:618-632.
100. Bruno R: Integration of population pharmacokinetics/pharmacodynamics in the clinical development and the registration dossier of docetaxel. In: COST B1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aarons L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):255-262.
101. Girard P, Nony P, Boisel JP: Can we model dose-response in real prescription environment? In: COST B1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aaror.s L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):59-66.
102. Mandema JW: Population pharmacokinetics/ pharmacodynamics of analgesics: Theory and applications. In: COSTB1 Medicine. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Aarons L, Balant L, Danhof M (Eds), European Commission, Brussels, Belgium (1997):75-82.
103. Sheiner LB, Beal SL, Dunne A: Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. JAm StatAss (1997) 92:1235-1244. • An important article demonstrating capabilities of modem mixedeffects modeling in the analysis of drug efficacy.
104. Ette El, Ludden TM: Population pharmacokinetic modeling: The importance of informative graphics. Pharm Res (1995) 12:1845-1855.
105. Ette El: Statistical graphics in pharmacokinetics and pharmacodynamics: A tutorial. Ann Pharmacother (1998) 32:818-828.
106. Jonsson EN, Karisson MO: Automated covariate model building within NONMEM. Pharm Res (1998) 15:1463-1468.
107. Jonsson EN, Karisson MO: Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamlc model building aid for NONMEM. Comput Methods Programs B/omed(1999) 58:51-64.
108. Sadray S, Jonsson EN, Karisson MO: Likelihood-based diagnostics for influential individuals in non-linear mixedeffects model selection. Pharm Res (1999) 16:1260-1265.
109. Fullerton T, Forrest A, Levy G: Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. J Pharm Sc/(1996) 85:600-607.
110. Hashimoto Y, Ozaki J, Koue T, Odani A, Yasuhara M, Hori R: Simulation for the analysis of distorted pharmacodynamic data. Pharm fles(1994) 11:545-548. • A direct comparison of the mixed-effects modeling method with the two stage and naTve-pooled data method that clearly demonstrates the advantages of the former in the analysis of complex pharmacodynamic data.
111. Hunt CA, Guzy S, Weiner DL: A forecasting approach to accelerate drug development Stat Med (1998) 17:1725-1740.
112. Charpiat B, Falcon! I, Breant V, Jelliffe RW, Sab JM, Ducerf C, Fourcade N, Thomasson A, Baulieux J: A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit (1998) 20:158-164.
113. Femandez de Gatta MM, Garcia MJ, Lanao JM, DominguezGil A: Bayesian forecasting In pédiatrie populations. Clin Pharmacokinet (1996) 31:325-330.
114. Kinowski JM, Bressolle F, Rodler M, Augey V, Fahre D, Richard JL, Galtier M, Gomeni R: A limited sampling model with Bayesian estimation to determine inulin pharmacokinetics using the population data modeling program P-PHARM. Clin Drug Invest (1995) 9:260-269.
115. Mentre F, Kovarik J, Gerbeau C: Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: An application to basiliximab in renal transplantation. J Pharmacokinet Biopharm (1999) 27:213-230.
116. Preechagoon Y, Charles B, Piotrovsky V, Donovan T, Van Peer A: Population pharmacokinetics of enterally administered cisapride in young infants with gastrooesophageal reflux disease. Br J Clin Pharmacol (1999) 48:688-693.